$RHE
Regional Health Properties Inc

2023 Q3 Form 10-Q Financial Statement

#000095017023043467 Filed on August 18, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $4.138M $4.598M
YoY Change -62.48% -43.19%
Cost Of Revenue $2.313M $2.159M
YoY Change -69.06% -48.86%
Gross Profit $1.825M $2.439M
YoY Change -48.65% -36.99%
Gross Profit Margin 44.1% 53.04%
Selling, General & Admin $1.506M $1.330M
YoY Change -66.41% -57.98%
% of Gross Profit 82.52% 54.53%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $526.0K $702.0K
YoY Change -12.33% 15.84%
% of Gross Profit 28.82% 28.78%
Operating Expenses $4.542M $4.412M
YoY Change -65.06% -48.83%
Operating Profit -$404.0K $186.0K
YoY Change -79.5% -135.16%
Interest Expense $708.0K $679.0K
YoY Change 25.53% 6.26%
% of Operating Profit 365.05%
Other Income/Expense, Net -$569.0K -$871.0K
YoY Change -135.56% 9.42%
Pretax Income -$973.0K -$685.0K
YoY Change 162.26% -48.3%
Income Tax
% Of Pretax Income
Net Earnings -$973.0K -$685.0K
YoY Change 162.26% -48.3%
Net Earnings / Revenue -23.51% -14.9%
Basic Earnings Per Share -$0.52 $22.68
Diluted Earnings Per Share -$0.52 $22.68
COMMON SHARES
Basic Shares Outstanding 1.883M 1.883M
Diluted Shares Outstanding 1.883M 1.883M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.427M $1.926M
YoY Change -39.87% -26.38%
Cash & Equivalents $1.400M $1.900M
Short-Term Investments
Other Short-Term Assets $4.111M $4.176M
YoY Change -3.84% 0.97%
Inventory
Prepaid Expenses
Receivables $2.035M $3.023M
Other Receivables $1.060M $772.0K
Total Short-Term Assets $8.633M $9.897M
YoY Change -34.47% -13.14%
LONG-TERM ASSETS
Property, Plant & Equipment $45.81M $46.27M
YoY Change -5.57% -5.72%
Goodwill $1.585M $1.585M
YoY Change 0.0% 0.0%
Intangibles $11.95M $12.06M
YoY Change -3.54% -3.51%
Long-Term Investments
YoY Change
Other Assets $4.000K $2.939M
YoY Change -98.99% 638.44%
Total Long-Term Assets $55.38M $55.96M
YoY Change -32.67% -36.54%
TOTAL ASSETS
Total Short-Term Assets $8.633M $9.897M
Total Long-Term Assets $55.38M $55.96M
Total Assets $64.01M $65.85M
YoY Change -32.92% -33.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.783M $3.036M
YoY Change -19.98% -31.45%
Accrued Expenses $4.806M $4.832M
YoY Change -29.88% -11.24%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.589M $7.868M
YoY Change -26.55% -20.31%
LONG-TERM LIABILITIES
Long-Term Debt $51.38M $52.03M
YoY Change -2.26% -1.21%
Other Long-Term Liabilities $4.655M $4.679M
YoY Change -82.52% -84.81%
Total Long-Term Liabilities $51.38M $52.03M
YoY Change -2.26% -1.21%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.589M $7.868M
Total Long-Term Liabilities $51.38M $52.03M
Total Liabilities $63.62M $64.58M
YoY Change -28.93% -30.82%
SHAREHOLDERS EQUITY
Retained Earnings -$81.66M -$80.69M
YoY Change -31.47% -32.07%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $387.0K $1.275M
YoY Change
Total Liabilities & Shareholders Equity $64.01M $65.85M
YoY Change -32.92% -33.86%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$973.0K -$685.0K
YoY Change 162.26% -48.3%
Depreciation, Depletion And Amortization $526.0K $702.0K
YoY Change -12.33% 15.84%
Cash From Operating Activities $505.0K $358.0K
YoY Change -19.46% -129.37%
INVESTING ACTIVITIES
Capital Expenditures $62.00K $852.0K
YoY Change -300.0% -1283.33%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$62.00K -$852.0K
YoY Change 100.0% 1083.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -673.0K -460.0K
YoY Change -6.92% -34.38%
NET CHANGE
Cash From Operating Activities 505.0K 358.0K
Cash From Investing Activities -62.00K -852.0K
Cash From Financing Activities -673.0K -460.0K
Net Change In Cash -230.0K -954.0K
YoY Change 81.1% -52.11%
FREE CASH FLOW
Cash From Operating Activities $505.0K $358.0K
Capital Expenditures $62.00K $852.0K
Free Cash Flow $443.0K -$494.0K
YoY Change -32.67% -56.93%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001004724
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Registrant Name
EntityRegistrantName
REGIONAL HEALTH PROPERTIES, INC.
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-33135
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
GA
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-5166048
dei Entity Address Address Line1
EntityAddressAddressLine1
1050 Crown Pointe Parkway
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 720
dei Entity Address City Or Town
EntityAddressCityOrTown
Atlanta
dei Entity Address State Or Province
EntityAddressStateOrProvince
GA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
30338
dei City Area Code
CityAreaCode
678
dei Local Phone Number
LocalPhoneNumber
869-5116
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1883028
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
46266000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
46611000
CY2023Q2 us-gaap Cash
Cash
1926000
CY2022Q4 us-gaap Cash
Cash
843000
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
2939000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
3066000
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
1400000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
1298000
CY2023Q2 us-gaap Receivables From Customers
ReceivablesFromCustomers
3023000
CY2022Q4 us-gaap Receivables From Customers
ReceivablesFromCustomers
6289000
CY2023Q2 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
1237000
CY2022Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
746000
CY2023Q2 us-gaap Notes Receivable Net
NotesReceivableNet
772000
CY2022Q4 us-gaap Notes Receivable Net
NotesReceivableNet
1099000
CY2023Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
2471000
CY2022Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
2471000
CY2023Q2 rhe Finite Lived Intangible Assets Lease Rights Net
FiniteLivedIntangibleAssetsLeaseRightsNet
98000
CY2022Q4 rhe Finite Lived Intangible Assets Lease Rights Net
FiniteLivedIntangibleAssetsLeaseRightsNet
110000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2677000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2848000
CY2023Q2 us-gaap Goodwill
Goodwill
1585000
CY2022Q4 us-gaap Goodwill
Goodwill
1585000
CY2023Q2 us-gaap Deferred Rent Receivables Net
DeferredRentReceivablesNet
2860000
CY2022Q4 us-gaap Deferred Rent Receivables Net
DeferredRentReceivablesNet
2912000
CY2023Q2 us-gaap Assets
Assets
65854000
CY2022Q4 us-gaap Assets
Assets
68580000
CY2023Q2 us-gaap Senior Long Term Notes
SeniorLongTermNotes
44554000
CY2022Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
45163000
CY2023Q2 us-gaap Longterm Transition Bond Current And Noncurrent
LongtermTransitionBondCurrentAndNoncurrent
5988000
CY2022Q4 us-gaap Longterm Transition Bond Current And Noncurrent
LongtermTransitionBondCurrentAndNoncurrent
6120000
CY2023Q2 us-gaap Other Long Term Debt
OtherLongTermDebt
1490000
CY2022Q4 us-gaap Other Long Term Debt
OtherLongTermDebt
895000
CY2023Q2 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
3036000
CY2022Q4 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
3293000
CY2023Q2 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
4832000
CY2022Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
5036000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
3044000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3226000
CY2023Q2 us-gaap Other Liabilities
OtherLiabilities
1635000
CY2022Q4 us-gaap Other Liabilities
OtherLiabilities
1131000
CY2023Q2 us-gaap Liabilities
Liabilities
64579000
CY2022Q4 us-gaap Liabilities
Liabilities
64864000
CY2022Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
55000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
55000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1894000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1793000
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1883000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1784000
CY2023Q2 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
62938000
CY2022Q4 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
62702000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-80691000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-121409000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
1275000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
3716000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
65854000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
68580000
CY2023Q2 us-gaap Revenues
Revenues
4598000
CY2022Q2 us-gaap Revenues
Revenues
8093000
us-gaap Revenues
Revenues
8504000
us-gaap Revenues
Revenues
14740000
CY2023Q2 rhe Patient Care Expense
PatientCareExpense
2159000
CY2022Q2 rhe Patient Care Expense
PatientCareExpense
4222000
rhe Patient Care Expense
PatientCareExpense
4697000
rhe Patient Care Expense
PatientCareExpense
6564000
CY2023Q2 rhe Facility Rent Expense
FacilityRentExpense
149000
CY2022Q2 rhe Facility Rent Expense
FacilityRentExpense
1634000
rhe Facility Rent Expense
FacilityRentExpense
297000
rhe Facility Rent Expense
FacilityRentExpense
3274000
CY2023Q2 rhe Cost Of Management Fees
CostOfManagementFees
146000
CY2022Q2 rhe Cost Of Management Fees
CostOfManagementFees
144000
rhe Cost Of Management Fees
CostOfManagementFees
286000
rhe Cost Of Management Fees
CostOfManagementFees
319000
CY2023Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
702000
CY2022Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
606000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1212000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1219000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1011000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
921000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2217000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2054000
CY2023Q2 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
24000
CY2022Q2 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
466000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
40000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
2227000
CY2023Q2 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
221000
CY2022Q2 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
629000
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
313000
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
968000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
4412000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
8622000
us-gaap Operating Expenses
OperatingExpenses
9062000
us-gaap Operating Expenses
OperatingExpenses
16625000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
186000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-529000
us-gaap Operating Income Loss
OperatingIncomeLoss
-558000
us-gaap Operating Income Loss
OperatingIncomeLoss
-1885000
CY2023Q2 us-gaap Interest Expense
InterestExpense
679000
CY2022Q2 us-gaap Interest Expense
InterestExpense
639000
us-gaap Interest Expense
InterestExpense
1359000
us-gaap Interest Expense
InterestExpense
1291000
CY2023Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
192000
CY2022Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
157000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
759000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
1076000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-871000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-796000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2118000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2367000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-685000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-1325000
us-gaap Profit Loss
ProfitLoss
-2676000
us-gaap Profit Loss
ProfitLoss
-4252000
CY2022Q2 rhe Preferred Stock Dividends Undeclared
PreferredStockDividendsUndeclared
2249000
rhe Preferred Stock Dividends Undeclared
PreferredStockDividendsUndeclared
4498000
CY2023Q2 rhe Preferred Stock Dividends Gain On Extinguishment
PreferredStockDividendsGainOnExtinguishment
43395000
rhe Preferred Stock Dividends Gain On Extinguishment
PreferredStockDividendsGainOnExtinguishment
43395000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
42710000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3574000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
40719000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8750000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
22.68
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
21.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.93
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
22.68
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
21.73
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.93
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1883028
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1768720
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1872636
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1775637
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1883253
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1768720
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1873489
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1775637
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3716000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
81000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-1992000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1805000
CY2023Q2 rhe Extinguishment Of Preferred Stock Value
ExtinguishmentOfPreferredStockValue
-61997000
CY2023Q2 rhe Adjustment Of Exchange Of Preferred Stock Value
AdjustmentOfExchangeOfPreferredStockValue
61997000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
155000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-685000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1275000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10396000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
111000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-46000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-2927000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
7534000
CY2022Q2 rhe Adjustments To Additional Paid In Capital Forfeitures Of Share Based Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalForfeituresOfShareBasedCompensationRequisiteServicePeriodRecognitionValue
4000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-1325000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6213000
us-gaap Profit Loss
ProfitLoss
-2676000
us-gaap Profit Loss
ProfitLoss
-4252000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1212000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1219000
us-gaap Share Based Compensation
ShareBasedCompensation
236000
us-gaap Share Based Compensation
ShareBasedCompensation
115000
rhe Rent Expense Less Than In Excess Of Cash Paid
RentExpenseLessThanInExcessOfCashPaid
-11000
rhe Rent Expense Less Than In Excess Of Cash Paid
RentExpenseLessThanInExcessOfCashPaid
153000
us-gaap Straight Line Rent Adjustments
StraightLineRentAdjustments
-236000
us-gaap Straight Line Rent Adjustments
StraightLineRentAdjustments
-73000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
37000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
44000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
40000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
2227000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3512000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3446000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-797000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-358000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-460000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1138000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
504000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-281000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2955000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2798000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
854000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
152000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-854000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-152000
us-gaap Repayments Of Senior Debt
RepaymentsOfSeniorDebt
624000
us-gaap Repayments Of Senior Debt
RepaymentsOfSeniorDebt
806000
us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
504000
us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
572000
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
17000
us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
50000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
46000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1145000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1374000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
956000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4324000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3909000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9848000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4865000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5524000
us-gaap Interest Paid Net
InterestPaidNet
1312000
us-gaap Interest Paid Net
InterestPaidNet
1256000
rhe Vendor Financed Insurance
VendorFinancedInsurance
962000
rhe Vendor Financed Insurance
VendorFinancedInsurance
1078000
rhe Exchange Of Preferred Stock Series A To Series B
ExchangeOfPreferredStockSeriesAToSeriesB
18602000
rhe Preferred Stock Dividends Gain On Extinguishment
PreferredStockDividendsGainOnExtinguishment
43395000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the unaudited consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates.</span></p>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reclassifications</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain reclassifications have been made to the amounts in prior periods in order to conform to the current period's presentation. A reclassification has been made to the stock balances on the consolidated statement of stockholders’ equity in prior periods in order to conform to the current period's presentation.</span></p>
CY2022Q4 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
3293000
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
52000000
CY2023Q2 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
1100000
CY2023Q2 rhe Long Term Debt Maturities Repayments Of Principal In Next Twelve Months Subject To Non Default In Payments
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonthsSubjectToNonDefaultInPayments
2500000
rhe Facility Rent Expense
FacilityRentExpense
3274000
CY2023Q2 rhe Penalty For Service Contract Non Performance
PenaltyForServiceContractNonPerformance
50000
CY2023Q2 rhe Percentage Of Reserve For Patient Care Revenue
PercentageOfReserveForPatientCareRevenue
0.015
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3000000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6300000
CY2023Q2 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
4423000
CY2022Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
7587000
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1400000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1298000
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3023000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6289000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1200000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
700000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
500000
CY2023Q2 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
3036000
us-gaap Other Expenses
OtherExpenses
500000
us-gaap Other Expenses
OtherExpenses
900000
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0385
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
46000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
52000
CY2023Q2 rhe Antidilutive Securities Excluded From Computation Of Earnings Per Share Intrinsic Value
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareIntrinsicValue
0
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1900000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3000000
rhe Accumulated And Unpaid Dividends On Series A Preferred Stock
AccumulatedAndUnpaidDividendsOnSeriesAPreferredStock
50400000
CY2023Q2 us-gaap Cash
Cash
1926000
CY2022Q4 us-gaap Cash
Cash
843000
CY2023Q2 us-gaap Replacement Reserve Escrow
ReplacementReserveEscrow
2094000
CY2022Q4 us-gaap Replacement Reserve Escrow
ReplacementReserveEscrow
2155000
CY2023Q2 rhe Escrow Deposit Current
EscrowDepositCurrent
452000
CY2022Q4 rhe Escrow Deposit Current
EscrowDepositCurrent
459000
CY2023Q2 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
317000
CY2022Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
317000
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
2939000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
3066000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4865000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3909000
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
68827000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
68327000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
22561000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
21716000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
46266000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
46611000
CY2023Q2 us-gaap Land Improvements
LandImprovements
100000
CY2023Q2 us-gaap Depreciation
Depreciation
593000
CY2022Q2 us-gaap Depreciation
Depreciation
496000
us-gaap Depreciation
Depreciation
993000
us-gaap Depreciation
Depreciation
1000000
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
109000
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
110000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
219000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
219000
CY2023Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
702000
CY2022Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
606000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1212000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1219000
CY2022Q4 rhe Finite And Indefinite Lived Intangible Assets Gross
FiniteAndIndefiniteLivedIntangibleAssetsGross
16953000
CY2022Q4 us-gaap Goodwill Gross
GoodwillGross
1585000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4678000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
12275000
CY2022Q4 us-gaap Goodwill
Goodwill
1585000
CY2023Q2 rhe Finite And Indefinite Lived Intangible Assets Gross
FiniteAndIndefiniteLivedIntangibleAssetsGross
16953000
CY2023Q2 us-gaap Goodwill Gross
GoodwillGross
1585000
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4898000
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
12055000
CY2023Q2 us-gaap Goodwill
Goodwill
1585000
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
109000
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
110000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
219000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
219000
rhe Operating Leases Number Of Skilled Nursing Facilities Leased
OperatingLeasesNumberOfSkilledNursingFacilitiesLeased
1
us-gaap Lessor Operating Lease Option To Terminate
LessorOperatingLeaseOptionToTerminate
The Company also leased certain office space located in Suwanee, Georgia through the termination date of June 30, 2023.
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y9M18D
CY2023Q2 rhe Lessee Operating Lease Liability Future Rental Payments Due Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityFutureRentalPaymentsDueRemainderOfFiscalYear
312000
CY2023Q2 rhe Lessee Operating Lease Accretion On Lease Liability Due Remainder Of Fiscal Year
LesseeOperatingLeaseAccretionOnLeaseLiabilityDueRemainderOfFiscalYear
7000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
305000
CY2023Q2 rhe Lessee Operating Lease Liability Future Rental Payments Due Year One
LesseeOperatingLeaseLiabilityFutureRentalPaymentsDueYearOne
633000
CY2023Q2 rhe Lessee Operating Lease Accretion Of Lease Liability Due Year One
LesseeOperatingLeaseAccretionOfLeaseLiabilityDueYearOne
50000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
582000
CY2023Q2 rhe Lessee Operating Lease Liability Future Rental Payments Due Year Two
LesseeOperatingLeaseLiabilityFutureRentalPaymentsDueYearTwo
645000
CY2023Q2 rhe Lessee Operating Lease Accretion Of Lease Liability Due Year Two
LesseeOperatingLeaseAccretionOfLeaseLiabilityDueYearTwo
97000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
549000
CY2023Q2 rhe Lessee Operating Lease Liability Future Rental Payments Due Year Three
LesseeOperatingLeaseLiabilityFutureRentalPaymentsDueYearThree
658000
CY2023Q2 rhe Lessee Operating Lease Accretion Of Lease Liability Due Year Three
LesseeOperatingLeaseAccretionOfLeaseLiabilityDueYearThree
141000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
517000
CY2023Q2 rhe Lessee Operating Lease Liability Future Rental Payments Due Year Four
LesseeOperatingLeaseLiabilityFutureRentalPaymentsDueYearFour
671000
CY2023Q2 rhe Lessee Operating Lease Accretion Of Lease Liability Due Year Four
LesseeOperatingLeaseAccretionOfLeaseLiabilityDueYearFour
184000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
487000
CY2023Q2 rhe Lessee Operating Lease Liability Future Rental Payments Due After Year Five
LesseeOperatingLeaseLiabilityFutureRentalPaymentsDueAfterYearFive
914000
CY2023Q2 rhe Lessee Operating Lease Accretion Of Lease Liability Due After Year Five
LesseeOperatingLeaseAccretionOfLeaseLiabilityDueAfterYearFive
310000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
604000
CY2023Q2 rhe Lessee Operating Lease Liability Future Rental Payments
LesseeOperatingLeaseLiabilityFutureRentalPayments
3833000
CY2023Q2 rhe Lessee Operating Lease Accretion Of Lease Liability
LesseeOperatingLeaseAccretionOfLeaseLiability
789000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3044000
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0385
rhe Number Of Owned Facilities Lessor
NumberOfOwnedFacilitiesLessor
9
rhe Number Of Owned Facilities
NumberOfOwnedFacilities
11
rhe Number Of Owned Facilities Sub Lessor
NumberOfOwnedFacilitiesSubLessor
1
rhe Weighted Average Remaining Lease Term Facilities Lessor
WeightedAverageRemainingLeaseTermFacilitiesLessor
P5Y9M18D
CY2023Q2 us-gaap Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year
LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
3139000
CY2023Q2 us-gaap Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
6187000
CY2023Q2 us-gaap Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
6034000
CY2023Q2 us-gaap Lessor Operating Lease Payments To Be Received Three Years
LessorOperatingLeasePaymentsToBeReceivedThreeYears
5362000
CY2023Q2 us-gaap Lessor Operating Lease Payments To Be Received Four Years
LessorOperatingLeasePaymentsToBeReceivedFourYears
5445000
CY2023Q2 us-gaap Lessor Operating Lease Payments To Be Received Thereafter
LessorOperatingLeasePaymentsToBeReceivedThereafter
11605000
CY2023Q2 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
37772000
CY2023Q2 rhe Accrued Payroll Related Expenses Current
AccruedPayrollRelatedExpensesCurrent
356000
CY2022Q4 rhe Accrued Payroll Related Expenses Current
AccruedPayrollRelatedExpensesCurrent
539000
CY2023Q2 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
2667000
CY2022Q4 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
2428000
CY2023Q2 us-gaap Self Insurance Reserve Current
SelfInsuranceReserveCurrent
65000
CY2022Q4 us-gaap Self Insurance Reserve Current
SelfInsuranceReserveCurrent
80000
CY2023Q2 us-gaap Interest Payable Current
InterestPayableCurrent
223000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
210000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
43000
CY2023Q2 rhe Medicaid Overpayment Healthcare Services
MedicaidOverpaymentHealthcareServices
52000
CY2022Q4 rhe Medicaid Overpayment Healthcare Services
MedicaidOverpaymentHealthcareServices
169000
CY2023Q2 rhe Insurance Escrow Current
InsuranceEscrowCurrent
55000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1414000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1567000
CY2023Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
4832000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
5036000
CY2023Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
53136000
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
53302000
CY2023Q2 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
988000
CY2022Q4 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
1005000
CY2023Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
116000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
119000
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
52032000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
52178000
CY2023Q2 rhe Debt Instrument Number Of Credit Related Instruments
DebtInstrumentNumberOfCreditRelatedInstruments
16
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Rolling Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths
1263000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo
1966000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree
2157000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour
8622000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive
1421000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling After Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive
37707000
CY2023Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
53136000
CY2023Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
116000
CY2023Q2 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
988000
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
52032000
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1883028
CY2023Q2 rhe Allocated Share Based Compensation Expense Benefit
AllocatedShareBasedCompensationExpenseBenefit
155000
CY2022Q2 rhe Allocated Share Based Compensation Expense Benefit
AllocatedShareBasedCompensationExpenseBenefit
4000
rhe Allocated Share Based Compensation Expense Benefit
AllocatedShareBasedCompensationExpenseBenefit
236000
rhe Allocated Share Based Compensation Expense Benefit
AllocatedShareBasedCompensationExpenseBenefit
115000
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
400000
CY2023Q2 rhe Facility Rent Expense
FacilityRentExpense
149000
CY2022Q2 rhe Facility Rent Expense
FacilityRentExpense
1634000
rhe Facility Rent Expense
FacilityRentExpense
297000
CY2023Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
37000
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P6Y7M6D
CY2023Q2 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
18.63
CY2023Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
37000
CY2023Q2 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
18.63
CY2023Q2 us-gaap Loss Contingency Pending Claims Number
LossContingencyPendingClaimsNumber
10
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
us-gaap Additional Information About Entitys Reportable Segments
AdditionalInformationAboutEntitysReportableSegments
(i) Real Estate Services, which consists of the leasing and subleasing of long-term care and senior living facilities to third-party tenants, including the Company's management of three facilities on behalf of third-party owners; and (ii) Healthcare Services, which consists of the operation of the Meadowood and Glenvue facilities.
CY2023Q2 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
1722000
CY2022Q2 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
3261000
us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
3430000
us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
7326000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4598000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8093000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8504000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14740000
CY2023Q2 rhe Patient Care Expense
PatientCareExpense
2159000
CY2022Q2 rhe Patient Care Expense
PatientCareExpense
4222000
rhe Patient Care Expense
PatientCareExpense
4697000
rhe Patient Care Expense
PatientCareExpense
6564000
CY2023Q2 rhe Cost Of Management Fees
CostOfManagementFees
146000
CY2022Q2 rhe Cost Of Management Fees
CostOfManagementFees
144000
rhe Cost Of Management Fees
CostOfManagementFees
286000
rhe Cost Of Management Fees
CostOfManagementFees
319000
CY2023Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
702000
CY2022Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
606000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1212000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1219000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1011000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
921000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2217000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2054000
CY2023Q2 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
24000
CY2022Q2 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
466000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
40000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
2227000
CY2023Q2 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
221000
CY2022Q2 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
629000
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
313000
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
968000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
4412000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
8622000
us-gaap Operating Expenses
OperatingExpenses
9062000
us-gaap Operating Expenses
OperatingExpenses
16625000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
186000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-529000
us-gaap Operating Income Loss
OperatingIncomeLoss
-558000
us-gaap Operating Income Loss
OperatingIncomeLoss
-1885000
CY2023Q2 us-gaap Interest Expense
InterestExpense
679000
CY2022Q2 us-gaap Interest Expense
InterestExpense
639000
us-gaap Interest Expense
InterestExpense
1359000
us-gaap Interest Expense
InterestExpense
1291000
CY2023Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
192000
CY2022Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
157000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
759000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
1076000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-871000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-796000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2118000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2367000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-685000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1325000
us-gaap Net Income Loss
NetIncomeLoss
-2676000
us-gaap Net Income Loss
NetIncomeLoss
-4252000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-23-043467-index-headers.html Edgar Link pending
0000950170-23-043467-index.html Edgar Link pending
0000950170-23-043467.txt Edgar Link pending
0000950170-23-043467-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rhe-20230630.htm Edgar Link pending
rhe-20230630.xsd Edgar Link pending
rhe-ex31_1.htm Edgar Link pending
rhe-ex31_2.htm Edgar Link pending
rhe-ex32_1.htm Edgar Link pending
rhe-ex32_2.htm Edgar Link pending
Show.js Edgar Link pending
rhe-20230630_cal.xml Edgar Link unprocessable
rhe-20230630_lab.xml Edgar Link unprocessable
rhe-20230630_def.xml Edgar Link unprocessable
rhe-20230630_pre.xml Edgar Link unprocessable
rhe-20230630_htm.xml Edgar Link completed